This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Delving into the Phase 2 DAHLIAS clinical trial of Nipocalimab in patients with Sjögren's disease.
Ticker(s): JNJWho's the expert?
Institution: Self
- Former Chief of Rheumatology at Baylor Medical Center and Director of Arthritis Centers of Texas before going in to private practice.
- Prescribed Krystexxa for 5 patients with uncontrolled Gout.
- Reviewed the data on the MIRROR trial from the EULAR meeting in January.
Interview Goalto discuss the current treatment landscape and the potential of Nipocalimab, a monoclonal antibody being developed by Johnson & Johnson for the treatment of Sjögren's disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
